EUVIMEDOpdag EUVIMED
Open access

Cardiovascular adverse events in patients with hepatocellular carcinoma receiving vascular endothelial growth factor inhibitors

Fangzheng Yuan iD, Carrie Lenneman, Ronald Krone iD, Grant R Williams iD, Darryl Outlaw iD, Michael Katsnelson iD, Stephen Lirette iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2024

DOI: 10.1002/phar.2896 ↗

At a glance

Journal article in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024. Written by Fangzheng Yuan and 6 co-authors. Institution: Department of Pharmacy, University of Alabama at Birmingham Hospital, Birmingham, Alabama, USA. Major MEDLINE topics: Carcinoma, Hepatocellular, Liver Neoplasms, Cardiovascular Diseases, Phenylurea Compounds. Cited 7 times so far (Crossref); 31 references. The full text is freely available in PubMed Central. Funded by: NHLBI NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Vascular endothelial growth factor inhibitors, including tyrosine kinase inhibitors (TKIs) and anti‐angiogenics, are first‐line therapies for advanced and metastatic hepatocellular carcinoma. Although TKIs have a greater potential for off‐target adverse effects compared with bevacizumab (anti‐angiogenics), a direct comparison of the risk of cardiovascular adverse events between these two types of therapies has not been performed.

Objective

To compare the incidence of and characterize cardiovascular adverse events in patients with hepatocellular carcinoma receiving TKIs versus bevacizumab.

Methods

This cohort study included adult patients with hepatocellular carcinoma who received first‐line TKIs (sorafenib or lenvatinib) or bevacizumab at two academic medical centers and one community cancer center from September 2018 to August 2021. The primary outcome was risk of cardiovascular adverse events. Major secondary outcomes included the incidence of individual types of cardiovascular adverse events and risk factors associated with major adverse cardiovascular events (MACE).

Results

The study included 221 patients (159 TKI patients; 62 bevacizumab patients). At a median follow‐up of 5 months, the probability of cardiovascular adverse events was not significantly different between the two groups (hazard ratio [HR]: 0.85; 95% confidence interval [95% CI]: 0.58–1.24; p = 0.390). The cumulative incidence of cardiovascular events was highest in patients receiving lenvatinib (sub‐distribution hazard ratio [SHR]: 1.53; 95% CI: 1.02–2.30) compared with those receiving sorafenib (reference) or bevacizumab (SHR: 1.05; 95% CI: 0.68–1.64) after adjustment for comorbidities, liver transplant status, and presence of portal vein thrombosis at baseline. Cardiovascular adverse events were observed in 151 (68%) patients, and MACE were observed in 27 (12%) patients. Risk factors associated with MACE were hypertension (SHR: 3.5; 95% CI: 0.9087–15.83; p = 0.086), prior history of MACE (SHR: 2.01; 95% CI: 0.83–4.87; p = 0.124), and tobacco use (SHR: 2.85; 95% CI: 0.90–8.97; p = 0.074).

Conclusions

Cardiovascular risk was not significantly different between TKIs and bevacizumab. Lenvatinib appears to have the highest risk of cardiovascular adverse events among these first‐line VEGF inhibitors.

Subjects

MeSH terms (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsCardiovascular DiseasesPhenylurea CompoundsQuinolinesAdultHumansBevacizumabVascular Endothelial Growth Factor ASorafenibCohort Studies

Author keywords

bevacizumabhepatocellular cancersorafenibtyrosine kinase inhibitor

Substances

BevacizumablenvatinibVascular Endothelial Growth Factor ASorafenibPhenylurea CompoundsQuinolines

Authors and institutions

  • Department of Pharmacy, University of Alabama at Birmingham Hospital, Birmingham, Alabama, USA.
  • Department of Research, Baptist Hospitals of Southeast Texas, Beaumont, Texas, USA.
  • Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.
  • Division of Cardiology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.

ORCID profiles: Fangzheng Yuan, Ronald Krone, Grant R Williams, Darryl Outlaw, Michael Katsnelson, Stephen Lirette

Funding

  • NHLBI NIH HHS

Cite

APA

Yuan, F., Lenneman, C., Krone, R., Williams, G. R., Outlaw, D., Katsnelson, M., & Lirette, S. (2024). Cardiovascular adverse events in patients with hepatocellular carcinoma receiving vascular endothelial growth factor inhibitors. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.2896

Vancouver

Yuan F, Lenneman C, Krone R, Williams GR, Outlaw D, Katsnelson M, et al. Cardiovascular adverse events in patients with hepatocellular carcinoma receiving vascular endothelial growth factor inhibitors. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2024. doi:10.1002/phar.2896

BibTeX
@article{Yuan2024,
  author = {Yuan, Fangzheng and Lenneman, Carrie and Krone, Ronald and Williams, Grant R and Outlaw, Darryl and Katsnelson, Michael and Lirette, Stephen},
  title = {Cardiovascular adverse events in patients with hepatocellular carcinoma receiving vascular endothelial growth factor inhibitors},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2024},
  doi = {10.1002/phar.2896}
}
Start for free →